top of page
Search
Women's health deserves better science, therapies and funding.
Our CEO Deana Mohr sat down with Precision Valley to discuss:
Why breaking the silence matters for patients and entrepreneurs
How to tackle challenges when the path isn't clear
What Europe needs to change to compete globally in scaling innovation
15 hours ago1 min read
MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer
Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of cell therapy pioneer Christine Günther, MD, PhD, as Chief Technology Officer (CTO), effective December 1, 2025. Dr. Günther brings more than 30 years of experience translating regenerative medicine innovations from development to clinical application. Dr. Günther
Dec 18, 20253 min read
MUVON Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Statistically Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
Dec 3, 20254 min read
Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025
Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as...
Jul 1, 20252 min read
INVEST IN OUR
INNOVATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page